Benefits
Rapid relief from nausea and vomiting
Effective in chemotherapy and postoperative settings
Suitable for IV and IM administration
High safety and tolerability profile
BP-compliant quality assurance
Usage Instructions
Administered intravenously (IV) or intramuscularly (IM) by healthcare professionals
Dosage depends on clinical indication and patient condition
Slow IV injection or infusion is recommended
For hospital and clinical use only
Mechanism of Action
Ondansetron selectively blocks serotonin (5-HT3) receptors in both the central nervous system and gastrointestinal tract. By inhibiting serotonin-mediated signaling, it prevents activation of the vomiting reflex.
Indications
Ondansetron Injection BP 8mg/4mL is indicated for the prevention and treatment of:
Chemotherapy-induced nausea and vomiting (CINV)
Radiotherapy-induced nausea and vomiting
Postoperative nausea and vomiting (PONV)
Severe vomiting requiring parenteral antiemetic therapy
Side Effects
Possible side effects include:
Headache
Constipation
Flushing
Elevated liver enzymes
QT interval prolongation (rare but serious)
Precautions
Use cautiously in patients with electrolyte imbalance
Monitor cardiac function in high-risk patients
Dose adjustment may be required in severe hepatic impairment
Avoid rapid IV bolus administration
Contraindications
Known hypersensitivity to ondansetron or other 5-HT3 receptor antagonists
Concomitant use with apomorphine
Patients with congenital long QT syndrome (use with caution)